Compare Alcon AG (ALC) vs KE Holdings Inc (BEKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs KE Holdings Inc — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while KE Holdings Inc trades at $15.36 (market cap $16.40B). The key difference: Alcon AG is the larger of the two by market cap, and KE Holdings Inc pays the higher dividend (1.86%). Which is the better fit depends on your goals.
| ALC | BEKE | |
|---|---|---|
Market Cap | $32.69B | $16.40B |
Sector | Health | Technology |
52-Week High | $92.22 | $20.36 |
52-Week Low | $62.02 | $14.26 |
Enterprise Value | $36.28B | $12.17B |
Dividend Yield | 0.54% | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
BEKE trades at $15.02, down 0.46% with a bearish technical signal. The company reported strong Q1 2026 earnings beating expectations with EPS of $0.20 versus $0.14 expected, driven by improved profitability despite lower revenue. Analyst sentiment remains overwhelmingly positive with 91.7% buy ratings. Recent news highlights potential trend reversal opportunities after a 14.1% decline over four weeks.
The outlook suggests potential upside with improving operational efficiency and cost controls offsetting market softness. Key risks include China's property market volatility and competitive pressures. With strong institutional support and positive earnings momentum, BEKE presents a compelling growth story despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →
